Author

G. L. Kelly

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 4 Approach:experimental assay· 4 Organism:mouse· 3 Research Focus:drug response / drug discovery· 2 Research Focus:benchmarking· 1 Assay:CRISPR screen· 1 Organism:Drosophila· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. Strasser· 3 shared G. Lessene· 2 shared L. Tai· 2 shared M. J. Herold· 2 shared A. J. Kueh· 1 shared A. Jeyasekharan· 1 shared A. R. Delbridge· 1 shared A. T. Papenfuss· 1 shared

Activity by Year

2018-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

A. Strasser

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

A Drosophila in vivo chemical screen reveals that combination drug treatment targeting MEK and DGKα mitigates Ras-driven polarity-impaired tumourigenesis.

H. E. Richardson, J. E. La Marca, R. W. Ely, S. T. Diepstraten, P. Burke, G. L. Kelly, P. O. Humbert

This paper identifies a combination of MEK and DGKα inhibitors that reduces Ras-driven tumourigenesis in Drosophila and human cells.

bioRxiv · Mar 14, 2022 · PreprintCancer Biology

Genome-wide in vivo CRISPR screens identify GATOR1 as a potent tumor suppressor in MYC-driven lymphomagenesis

M. A. Potts, S. Mizutani, Y. Deng, S. Vaidyanathan, K. Ting, G. Giner, S. Shruti, Y. Liao, S. Diepstraten, A. J. Kueh, M. Pal, G. Healey, L. Tai, Z. Wang, C. Koenig, , M. J. Herold

The paper identifies GATOR1 as a tumor suppressor in MYC-driven lymphomagenesis using in vivo CRISPR screens and shows its sensitivity to mTOR inhibitors.

bioRxiv · Feb 16, 2022 · PreprintCancer Biology

BCL-XL is essential for the protection from secondary anemia caused by radiation-induced fatal kidney damage

K. Brinkmann, P. Waring, S. Glaser, V. Wimmer, D. Nhu, L. Whitehead, A. R. Delbridge, G. Lessene, M. Herold, G. L. Kelly, S. Grabow, A. Strasser

The paper shows that BCL-XL protects adult kidneys from radiation-induced damage, leading to secondary anemia, and highlights its importance in cancer therapy combinations.

bioRxiv · Apr 28, 2020 · PreprintPharmacology & Toxicology

Humanized Mcl-1 mice enable accurate pre-clinical evaluation of MCL-1 inhibitors destined for clinical use

M. S. Brennan, C. Chang, G. Dewson, L. Tai, G. Lessene, A. Strasser, G. L. Kelly, M. J. Herold

This study develops a humanized Mcl-1 mouse model to evaluate MCL-1 inhibitors, showing improved sensitivity to S63845 and effective tumor remission in pre-clinical trials.

bioRxiv · Jun 14, 2018Cancer Biology